Focal Segmental Glomerulosclerosis Market
Focal Segmental Glomerulosclerosis Market Size, Share & Trends Analysis RepoBy Disease Type (Primary FSGS, Secondary FSGS), By Diagnosis (Kidney Biopsy, Blood Tests, Urine Tests, Genetic Testing) By Treatment (Pharmacological Therapy [Corticosteroids, Calcineurin Inhibitors, RAAS Inhibitors, Emerging Targeted Therapies such as Sparsentan], Dialysis, Kidney Transplant) Forecast Period, (2026-2035)
Industry Overview
Focal Segmental Glomerulosclerosis market was valued at $1,208.0 million in 2025 and is projected to reach $2,100.6 million by 2035, growing at a CAGR of 5.8% during the forecast period (2026-2035). The Focal Segmental Glomerulosclerosis market is expanding due to increasing clinical recognition of rare kidney disorders and improved diagnostic accuracy through biopsy and genetic testing. Advancements in targeted pharmacological therapies, including novel endothelin receptor antagonists, are strengthening treatment adoption across specialized nephrology settings. Rising prevalence of chronic kidney disease and associated proteinuria management strategies continues to support demand for corticosteroids, calcineurin inhibitors, and RAAS inhibitors. Growth in renal replacement procedures, particularly dialysis and transplant-related immunosuppression, contributes additional commercial momentum. Ongoing clinical research and regulatory progress surrounding disease-specific therapies are expected to reinforce long-term market development.
Market Dynamics
Rising Diagnosis and Treatment Adoption in Rare Kidney Disorders
The Focal Segmental Glomerulosclerosis market is supported by rising diagnosis rates driven by wider use of kidney biopsy, advanced laboratory testing, and growing adoption of genetic screening in specialized nephrology centers. Earlier identification of proteinuric kidney disorders has increased patient eligibility for pharmacological intervention, particularly corticosteroids and calcineurin inhibitors. Clinical emphasis on preserving renal function and delaying disease progression continues to sustain prescription volumes of RAAS inhibitors and immunosuppressive therapies. Expansion of clinical guidelines that recommend structured monitoring of nephrotic syndrome has also strengthened treatment adherence. In addition, improved awareness among healthcare professionals regarding rare glomerular diseases has reduced underdiagnosis, leading to a more consistent patient pool receiving active therapy.
Emergence of Targeted Therapies and Advanced Renal Care
Market growth is further driven by advancements in targeted drug development focused on podocyte protection and reduction of proteinuria, including emerging therapies such as sparsentan. Pharmaceutical investment in rare kidney disease research has accelerated clinical trials and regulatory engagement, improving confidence in disease-specific treatment pathways. Increasing utilization of dialysis and transplant-related immunosuppression among patients with advanced disease stages contributes steady product demand. Favorable reimbursement frameworks for rare disease treatments in key healthcare systems encourage adoption of novel pharmacological options. Continuous improvements in transplant management protocols and long-term immunosuppressive regimens also sustain recurring revenue streams linked to FSGS care.
Market Segmentation
- Based on disease type, the Focal Segmental Glomerulosclerosis market is segmented into primary FSGS, secondary FSGS, and genetic FSGS.
- Based on diagnosis and treatment, the market is segmented into kidney biopsy, blood tests, urine tests, genetic testing, pharmacological therapy (corticosteroids, calcineurin inhibitors, RAAS inhibitors, emerging targeted therapies such as sparsentan), dialysis, and kidney transplant.
Established Clinical Focus: Primary FSGS Dominance
Primary FSGS represents the largest share of diagnosed cases due to its direct clinical identification and higher treatment intensity compared with secondary forms. Early intervention strategies centered on immunosuppressive regimens continue to sustain consistent prescription demand. Nephrology guidelines emphasize aggressive proteinuria management, which reinforces adoption of calcineurin inhibitors and corticosteroids. Leading pharmaceutical participants such as Astellas Pharma and Novartis maintain strong positioning through established transplant and immunology portfolios. Expansion of specialized renal clinics has improved patient tracking and therapy continuity. Recent trends indicate increased integration of genetic screening to refine diagnosis and support personalized treatment selection.
Accelerating Innovation: Emergence of Targeted Therapies
Emerging targeted therapies represent the fastest growing sub segment, driven by advances in podocyte-focused mechanisms and endothelin pathway inhibition. Development activity from companies such as Travere Therapeutics reflects growing industry interest in disease-specific drug design. Clinical studies highlighting reductions in proteinuria are encouraging wider physician confidence in next-generation pharmacological options. Regulatory progress and orphan-disease incentives are strengthening commercialization pathways for novel molecules. Increased collaboration between biotech developers and nephrology research centers has accelerated late-stage trial momentum. Market trends suggest gradual transition from broad immunosuppression toward more selective therapeutic approaches.
Regional Outlook
The global focal segmental glomerulosclerosis market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Advancing Treatment Adoption across North America
North America maintains a strong position due to established nephrology infrastructure and high awareness of rare renal disorders among clinicians. Increased utilization of genetic testing and structured biopsy protocols continues to refine patient identification. Pharmaceutical innovators are expanding clinical programs focused on targeted therapies, contributing to evolving treatment standards. Key industry participants such as Travere Therapeutics, Pfizer, and Novartis maintain active engagement through research collaborations and product commercialization. Favorable reimbursement pathways for rare disease therapies support steady uptake of advanced pharmacological options. Recent trends reflect growing emphasis on precision medicine approaches within specialized renal centers.
Expanding Clinical Access and Research Activity in Europe
Europe demonstrates consistent market expansion supported by coordinated regulatory frameworks and strong academic research networks in nephrology. Public healthcare systems encourage early diagnosis through standardized screening and monitoring practices. Regional pharmaceutical leaders, including Sanofi and Astellas Pharma, continue to strengthen their presence through immunology and transplant-focused portfolios. Collaborative clinical trials across major European countries are accelerating evaluation of novel therapeutic mechanisms. Increased integration of genetic diagnostics within university hospitals is shaping more individualized treatment pathways. Recent developments highlight a gradual shift toward targeted therapies alongside established immunosuppressive regimens.
Market Players Outlook
The major companies operating in the global focal segmental glomerulosclerosis market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Travere Therapeutics, Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2026, Travere Therapeutics, Inc., announced that the US Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 2026.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global focal segmental glomerulosclerosis Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Focal Segmental Glomerulosclerosis Market Sales Analysis – Disease Type | Diagnosis | Treatment ($ Million)
- Focal Segmental Glomerulosclerosis Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Focal Segmental Glomerulosclerosis Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Focal Segmental Glomerulosclerosis Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Focal Segmental Glomerulosclerosis Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Focal Segmental Glomerulosclerosis Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Focal Segmental Glomerulosclerosis Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Focal Segmental Glomerulosclerosis Market Revenue and Share by Manufacturers
- Focal Segmental Glomerulosclerosis Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Astellas Pharma Inc.,
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Travere Therapeutics, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Astellas Pharma Inc.,
- Key Company Analysis
- Global Focal Segmental Glomerulosclerosis Market Sales Analysis by Disease Type ($ Million)
- Primary FSGS
- Secondary FSGS
- Global Focal Segmental Glomerulosclerosis Market Sales Analysis by Diagnosis ($ Million)
- Kidney Biopsy
- Blood Tests
- Urine Tests
- Genetic Testing
- Global Focal Segmental Glomerulosclerosis Market Sales Analysis by Treatment ($ Million)
- Pharmacological Therapy
- Corticosteroids
- Calcineurin Inhibitors
- RAAS Inhibitors
- Dialysis
- Kidney Transplant
- Pharmacological Therapy
- Regional Analysis
- North American Focal Segmental Glomerulosclerosis Market Sales Analysis – Disease Type | Diagnosis | Treatment | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Focal Segmental Glomerulosclerosis Market Sales Analysis – Disease Type | Diagnosis | Treatment | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Focal Segmental Glomerulosclerosis Market Sales Analysis – Disease Type | Diagnosis | Treatment | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Focal Segmental Glomerulosclerosis Market Sales Analysis – Disease Type | Diagnosis | Treatment | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Akebia Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Baxter International Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Calliditas Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CSL Vifor
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fresenius Medical Care AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc (GSK)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson (Janssen)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche Holding AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Focal Segmental Glomerulosclerosis Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
2. Global Primary FSGS Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Secondary FSGS Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Focal Segmental Glomerulosclerosis Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
5. Global Kidney Biopsy Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Blood Tests Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Urine Tests Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Genetic Testing Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Focal Segmental Glomerulosclerosis Market Research and Analysis by Treatment, 2025–2035 ($ Million)
10. Global Pharmacological Therapy Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Corticosteroids Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Calcineurin Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global RAAS Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Dialysis Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Kidney Transplant Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Focal Segmental Glomerulosclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
17. North American Focal Segmental Glomerulosclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
18. North American Focal Segmental Glomerulosclerosis Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
19. North American Focal Segmental Glomerulosclerosis Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
20. North American Focal Segmental Glomerulosclerosis Market Research and Analysis by Treatment, 2025–2035 ($ Million)
21. European Focal Segmental Glomerulosclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
22. European Focal Segmental Glomerulosclerosis Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
23. European Focal Segmental Glomerulosclerosis Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
24. European Focal Segmental Glomerulosclerosis Market Research and Analysis by Treatment, 2025–2035 ($ Million)
25. Asia-Pacific Focal Segmental Glomerulosclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
26. Asia-Pacific Focal Segmental Glomerulosclerosis Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
27. Asia-Pacific Focal Segmental Glomerulosclerosis Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
28. Asia-Pacific Focal Segmental Glomerulosclerosis Market Research and Analysis by Treatment, 2025–2035 ($ Million)
29. Rest of the World Focal Segmental Glomerulosclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
30. Rest of the World Focal Segmental Glomerulosclerosis Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
31. Rest of the World Focal Segmental Glomerulosclerosis Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
32. Rest of the World Focal Segmental Glomerulosclerosis Market Research and Analysis by Treatment, 2025–2035 ($ Million)
1. Global Focal Segmental Glomerulosclerosis Market Share by Disease Type, 2025 vs 2035 (%)
2. Global Primary FSGS Market Share by Region, 2025 vs 2035 (%)
3. Global Secondary FSGS Market Share by Region, 2025 vs 2035 (%)
4. Global Focal Segmental Glomerulosclerosis Market Share by Diagnosis, 2025 vs 2035 (%)
5. Global Kidney Biopsy Market Share by Region, 2025 vs 2035 (%)
6. Global Blood Tests Market Share by Region, 2025 vs 2035 (%)
7. Global Urine Tests Market Share by Region, 2025 vs 2035 (%)
8. Global Genetic Testing Market Share by Region, 2025 vs 2035 (%)
9. Global Focal Segmental Glomerulosclerosis Market Share by Treatment, 2025 vs 2035 (%)
10. Global Pharmacological Therapy Market Share by Region, 2025 vs 2035 (%)
11. Global Corticosteroids Market Share by Region, 2025 vs 2035 (%)
12. Global Calcineurin Inhibitors Market Share by Region, 2025 vs 2035 (%)
13. Global RAAS Inhibitors Market Share by Region, 2025 vs 2035 (%)
14. Global Dialysis Market Share by Region, 2025 vs 2035 (%)
15. Global Kidney Transplant Market Share by Region, 2025 vs 2035 (%)
16. Global Focal Segmental Glomerulosclerosis Market Share by Region, 2025 vs 2035 (%)
17. US Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
18. Canada Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
19. UK Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
20. France Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
21. Germany Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
22. Italy Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
23. Spain Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
24. Russia Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
25. Rest of Europe Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
26. India Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
27. China Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
28. Japan Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
29. South Korea Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
30. Australia and New Zealand Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
31. ASEAN Economies Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
32. Rest of Asia-Pacific Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
33. Latin America Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
34. Middle East and Africa Focal Segmental Glomerulosclerosis Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
